dementia
-
Innovations in Dementia Care: Exploring the Role of Medical Devices and Medications
Dementia patients require a balanced blend of supportive devices, effective medications such as cholinesterase inhibitors and holistic understanding to truly enjoy the best possible quality of life.
-
Covid is Still With Us. What Does That Mean for Your Brain?
We may not fully understand the link between Covid-19 and Alzheimer’s, but we already have the scientific research and tools to address people’s fears, support their cognitive health journey, and reverse the increase of Alzheimer’s.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Ending Involuntary Commitments Would Shift Burden of Montana’s Dementia Care to Strapped Communities
A budget estimate attached to proposed legislation in Montana raises questions about whether the state’s cash-strapped communities will have the capacity to care for patients with Alzheimer’s disease, other types of dementia or traumatic brain injuries by July 2025, when involuntary commitments would cease under the plan.
-
This Startup is Proving that Family Caregivers Have the Power to Lower Admissions and Reduce Costs
Reducing hospitalizations for frail elderly members is a major challenge for Medicare Advantage payers and providers. The key to avoiding any hospitalization is to detect and address a change in condition before it worsens. Ceresti Co-founder and CEO Dirk Soenksen talks about how his company is addressing these needs.
-
Dementia: Lifestyle Habits Are Way More Important Than We Think
Ideally, novel therapeutics will be introduced in combination with lifestyle interventions that are going to need to be personalized to each individual, and anchored in reliable, longitudinal metrics to enable modifications as needed.
-
MedCity Influencers, BioPharma
Lewy body dementia – Do you even know what that is?
Too many of us and our families have been affected by dementia in one form or another. October is recognized by patients, advocates and the medical community as Lewy Body Dementia Awareness month, and perhaps this year it will mark new hope for those suffering from this disease.
-
Mental health startup for seniors rakes in $32M from General Catalyst, Mass General Brigham Ventures, others
There is a dearth of professionals with licenses and training to provide care for seniors’ mental and behavioral health challenges — such as Alzheimer’s and other dementias, anxiety and depression. Seattle-based Rippl Care is seeking to change this. The startup just closed a $32 million seed funding round led by ARCH Venture Partners and General Catalyst.
-
Neuro-focused Arkuda raises $64M as dementia drug moves closer to the clinic
Eli Lilly is among the new investors joining the Series B round of Arkuda Therapeutics, a biotech developing a drug to treat a rare, inherited form of dementia. If the biotech’s approach works, it could also have applications in other neurodegenerative conditions such as Alzheimer’s and Parkinson’s.
-
Digital health’s ‘wow factor’ should focus on the patient
While the era of using digital health tools to manage MCI and perhaps prevent greater cognitive decline is just beginning, it is a promising new therapeutic direction for a very complex condition. The more these solutions are developed and studied, it seems clear, however, that the most effective technology will be the systems that individuals with MCI and their caregivers consistently enjoy using over the long term.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Neuroglee looks to Mayo partnership, digital therapeutics to tackle mild cognitive impairment
Neuroglee recently raised $10 million in funding and struck a partnership with Mayo Clinic. It’s building a digital therapeutic and virtual programs for people with mild cognitive impairment.
-
Merck, Evidation to test if smartphone data can be used to detect early Alzheimer’s
Merck and Evidation Health launched a study to see if data from smartphones and wearables could be used to detect and monitor the treatment of Alzheimer’s Disease.
-
FDA rejects Acadia’s bid for Nuplazid approval in dementia-related psychosis
The FDA’s rejection of Nuplazid cited clinical trial results in subgroups of patients. Acadia Pharmaceuticals said the FDA’s decision goes against all feedback the company previously received and amounts to an incorrect way of evaluating dementia patients.
-
Biogen, Apple to launch virtual study on cognitive health
Biogen plans to launch a virtual study with Apple this year to identify early signs of mild cognitive impairment. The study is expected to launch in the second half of 2021.
-
Devices & Diagnostics, Health Tech
Evidation Health and Eli Lilly study uses Apple devices and apps to predict cognitive impairment
Early results from a study conducted by Evidation Health, Eli Lilly and Apple have shown the ability to detect cognitive decline and mild Alzheimer’s disease using a combination of Apple wearables, mobile devices, digital apps and sleep sensors.
-
An advanced directive for patients with dementia that would offer way to withhold food or water faces challenges
Whether assisted feeding can be withdrawn was at the center of recent high-profile cases in which patients with dementia were spoon-fed against their documented wishes because they continued to open their mouths.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
